|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.510 SEK | -0.93% |
|
-4.27% | -36.96% |
| 06-26 | Vivesto Completes Enrollment in Canine Study | FW |
| 06-16 | Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study | CI |
| Market Cap | 94.22M 9.69M 8.48M 7.83M 7.31M 13.76M 916M 14.08M 36.37M 452M 36.37M 35.58M 1.57B | P/E 2026 * |
-2.78x | P/E 2027 * | -2.03x |
|---|---|---|---|---|---|
| Enterprise Value | 86.22M 8.86M 7.76M 7.16M 6.69M 12.59M 838M 12.88M 33.28M 413M 33.29M 32.56M 1.44B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vivesto AB
| 1 day | -0.93% | ||
| 1 week | -4.27% | ||
| Current month | -20.76% | ||
| 1 month | -20.76% | ||
| 3 months | +5.06% | ||
| 6 months | -39.56% | ||
| Current year | -36.96% |
| 1 week | 8.22 |  | 8.9 |
| 1 month | 8.22 | | 10.7 |
| Current year | 7 | | 19.5 |
| 1 year | 7 | | 31.9 |
| 3 years | 7 | | 90.6 |
| 5 years | 7 | | 319 |
| 10 years | 7 | | 1,670 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 68 | 22/01/2023 |
Robert Maiorana
DFI | Director of Finance/CFO | 66 | 30/06/2022 |
| Chief Tech/Sci/R&D Officer | 39 | 31/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 24/05/2022 | |
Hege Hellstrom
BRD | Director/Board Member | 61 | 25/09/2019 |
Pål Ryfors
BRD | Director/Board Member | 43 | 24/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/03/22 | Buy | Chief Executive Officer | 12,200 | 0.0027% | ||
| 23/03/22 | Others | Chairman | 120,000 | 0.0268% | ||
| 19/12/21 | Free | Chief Financial Officer | 1,350,000 | 0.3011% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93% | -4.27% | -62.76% | -70.24% | 9.69M | |
| +1.81% | +11.60% | +58.61% | +164.79% | 1,097B | |
| +1.51% | +11.77% | +69.61% | +57.53% | 622B | |
| +0.38% | +10.56% | +39.49% | +90.88% | 449B | |
| +0.83% | +6.34% | +29.51% | +24.01% | 334B | |
| -0.14% | +7.58% | +39.85% | +27.25% | 294B | |
| -0.06% | +4.92% | +31.21% | +41.59% | 286B | |
| -0.96% | +4.98% | -28.02% | -40.96% | 213B | |
| +0.62% | +4.59% | +30.10% | +63.03% | 195B | |
| -1.21% | +1.17% | +14.15% | +66.20% | 157B | |
| Average | +0.03% | +5.68% | +22.18% | +42.41% | 364.67B | |
| Weighted average by Cap. | +0.64% | +8.72% | +43.31% | +82.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -31M -3.19M -2.79M -2.58M -2.41M -4.53M -301M -4.63M -11.97M -149M -11.97M -11.71M -516M | -46M -4.73M -4.14M -3.82M -3.57M -6.72M -447M -6.87M -17.76M -221M -17.76M -17.37M -766M |
| Net Debt | -8M -822K -720K -665K -621K -1.17M -77.76M -1.2M -3.09M -38.36M -3.09M -3.02M -133M | -10M -1.03M -900K -831K -776K -1.46M -97.19M -1.49M -3.86M -47.95M -3.86M -3.78M -166M |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/06/26 | SEK 8.510 | -0.93% | 26,238 |
| 26/06/26 | SEK 8.590 | -0.12% | 7,119 |
| 25/06/26 | SEK 8.600 | -3.15% | 4,945 |
| 24/06/26 | SEK 8.880 | -0.22% | 24,582 |
| 23/06/26 | SEK 8.900 | +0.11% | 20,265 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VIVE Stock
Select your edition
All financial news and data tailored to specific country editions
